Decoding dangerous death: How cytotoxic chemotherapy invokes inflammation, immunity or nothing at all

Cell Death and Differentiation

Volumn 15, Issue 1, 2008, Pages 13-20

  van der Most, R G ^a   Currie, A J ^a   Robinson, B W S ^a   Lake, R A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DENDRITIC CELL VACCINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GLYCOPROTEIN GP 96; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; MITOMYCIN C; NATURAL KILLER CELL RECEPTOR NKG2D; ONCOPHAGE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; URIC ACID;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BACTERIAL INFECTION; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL STRESS; CLINICAL TRIAL; COLORECTAL CANCER; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; METASTASIS POTENTIAL; NEOPLASM; NONHUMAN; OXIDATION REDUCTION REACTION; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

ANIMALS; APOPTOSIS; CELL DEATH; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; INFECTION; INFLAMMATION; NEOPLASMS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 37349062063     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402255     Document Type: Review

References (74)

1. Lake RA, Robinson BW. Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 2005; 5: 397-405.
2. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-1701.
3. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61.
4. Skobeme M, Beignon AS, Larsoon M, Bhardwaj N. Apoptotic cells at the crossroads of tolerance and immunity. Curr Top Microbiol Immunol 2005; 289: 259-292.
5. Matzinger P. The danger model: A renewed sense of self. Science 2002; 298: 301-305.
6. Matzinger P. Friendly and dangerous signals: Is the tissue in control? Nat Immunol 2007; 8: 11-13.
7. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006; 311 1-16.
8. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007; 13: 543-551.
9. Roberts ZJ, Goutagny N, Perera PY, Kato H, Kumar H, Kawai T et al. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med 2007; 204: 1559-1569.
10. Chiang E, Deng O, Anderson K, Matsuzawa A, Ichijo H, David M. Cutting edge: Apoptosis-regulating signal kinase 1 is required for reactive oxygen species-mediated activation of IFN regulatory factor 3 by lipopolysaccharide. J Immunol 2006; 176: 5720-5724.
11. Matsuzawa A, Saegusa K, Noguchi T, Sadamitsu C, Nishitoh H, Nagal S et al. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol 2005; 6: 587-592.
12. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L et al. Toll-like receptor 3 promotes crow-priming to virus-infected cells. Nature 2005; 433: 887-892.
13. Hiscott J. Another detour on the Toll road to the interferon antiviral response. Nat Struct Mol Biol 2004; 11: 1028-1030.
14. Ruckdeschel K, Pfaffinger G, Haase R, Sing A, Weighardt H, Hacker G et al. Signaling of apoptosis through TLRs critically Involved toll/IL-1 receptor domain-containing adapter nducing IFN-beta, but not MyD88, in bacteria-infected murine macrophages. J Immunol 2004; 173 3320-3328.
15. Salaun B, Coste I, Rissoan MC, Lebacque Si, Renno T. TLR3 can directly trigger apoptosis in human cancer calls. J Immunol 2006; 176 4894-4901.
16. Huang. B, Zhao J, Li H, He KL, Chen Y, Chen SH et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005; 65: 5009-5014.
17. Huang B, Zhao J, Shen S, Li H, He KL, Shen GX et al. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res 2007; 67: 4346-4352.
18. Rock KL, Heam A, Chen CJ, Shi Y. Natural endogenous adjuvants. Springer Semin Immunopathol 2005; 26: 231-246.
19. Zeh III HJ, Lotze MT. Addicted to death: Invasive cancer and the immune response to unscheduled cell death. J Immunother (1997) 2005; 28: 1-9.
20. Okabe Y, Kawane K, Akira S, Taniguchi T, Negate S. Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J Exp Med 2005; 202: 1333-1339.
21. Ishii KJ, Coban C, Kato H, Takahashi K, Torii Y, Takeshita F et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 2006; 7: 40-48.
22. Cheng G, Zhong J, Chung J, Chisari FV. Double-stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cells. Proc Natl Acad Sci USA 2007; 104: 9035-9040.
23. Stetson DB, Medzhitov R. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 2006; 24: 93-103.
24. Bennett RL, Blalock WL, Abtahi DM, Pan Y, Moyer SA, May WS. RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy, and viral infection. Blood 2006; 108: 821-829.
25. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A et al. Masquerader: High mobility group box-1 and cancer. Clin Cancer Res 2007; 13: 2836-2848.
26. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-342.
27. Ito N, DeMarco RA, Mailliard RB, Han J, Rabinowich H, Kalinski P et al. Cytolylic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol 2007; 81: 75-83.
28. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290: C917-C924.
29. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13 1050-1059.
30. Tian J, Avalos AM, Mao SY, Chen B, Senthil Y, Wu H et al. Toll-like receptor 9-dependent activation of DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8 487-496.
31. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: Repercussions in cancer therapy. J Leukoc Biol 2007; 81: 15-27.
32. Binder RJ, Srivastava PK. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the crow-priming of CD8+ T cells. Nat Immunol 2005; 6: 593-599.
33. Castelli C, Rivoltini L, Rini F, Belli F, Testori A, Maio M et al. Heat shock proteins: Biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol Immunother 2004; 53: 227-233.
34. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425 516-521.
35. Shi Y, Galusha SA, Rock KL, Cutting edge: Elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model J Immunol 2006; 176 3905-3908.
36. Hu DE, Moore AM, Thomsen LL, Brindle KM. Uric acid promotes tumor immune rejection. Cancer Res 2004; 64: 5059-5062.
37. Gernici C. Tumour lysis syndrome in solid tumours. Clin Oncol (R Coll Radiol) 2006; 18: 773-780.
38. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: First line of the immune response to cell stress. Cell 2006; 126: 659-662.
39. Kanneganti TD, Ozoren N, Body-Malapel M, Amer A, Park JH, Franchi L et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006;440:233-236.
40. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflamasome. Nature 2006; 440: 237-241.
41. Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: Master switches of inflammation. Cell Death Differ 2007; 14: 10-22.
42. Chen CJ, Shi Y, Heam A, Fitzgerald K, Golenbock D, Reed G et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006; 116: 2262-2271.
43. Scott P, Ma H, Vinyakosol S, Terkeltaub R, Liu-Bryan R. Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals. J Immunol 2006; 177: 6370-6378.
44. Kanellis J, Watanabe S, Li JH, Kong DH, Li P, Nakagawa T et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003; 41: 1287-1293.
45. Gorman A, McGowan A, Cotter TG. Role of peroxide and superoxide anion during tumour cell apoptosis. FEBS Lett 1997; 404: 27-33.
46. Jovasevic VM, Mokyr MB. Melphalan-induced expression of IFN-beta in MOPC-315 tumor-bearing mice and its importance for the up-regulation of TNF-alpha expression. J Immunol 2001; 167: 4895-4901.
47. Donepudi M, Raychaudhuri P, Bluestone JA, Mokyr MB. Mechanism of melphalan-induced B7-1 gone expression in P815 tumor cells. J Immunol 2001; 166: 6491-6499.
48. Zhao, T, Yang L, Sun Q, Arguello M, Ballard DW, Hiscott J et al. The NEMO adaptor bridges the nuclear factor-kappaB and interferon regulatory factor signaling pathways. Nat Immunol 2007; 8: 592-600.
49. Chiang CL, Ledemann JA, Rad AN, Katz DR, Chain BM. Hypochlorous acid enhances immunogenicifty and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells. Cancer Immunol Immunother 2006; 55: 1384-1395.
50. Alavi AS, Acevedo L, Min W, Cheresh DA. Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. Cancer Res 2007; 67: 2766-2772.
51. North RJ, Awwad M. Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cyding CD8+ T cells to cause regression of an advanced lymphoma. Immunology 1990; 71: 90-95.
52. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641-648.
53. Schiavoni G, Mattei F; Di Pucchio T, Santini SM, Bracci L, Belardelli F et al. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: Implications for strategies of chomoimmunotherapy of cancer. Blood 2000;95:2024-2030.
54. Mokyr MB, Place AT, Artwohl JE, Valli VE. Importance of Signaling via the IFN-alpha/beta receptpr on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother 2006; 55: 459-468.
55. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436: 1186-1190.
56. Gasser S, Raulet DH. The DNA damage response arouses the immune system. Cancer Res 2006; 66: 3959-3962.
57. Bui JD, Carayannopoulos LN, Lanier LL, Yokoyama WM, Schreiber RD. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol 2006, 176: 905-913.
58. Wiemann K, Mittrucker HW, Feger U, Welte SA, Yokoyama WM, Spies T et al. Systemic NKG2D down-regulation impairs Nk and CD8 T cell responses in vivo J Immunol 2005; 175: 720-729.
59. Coudert JD, Zimmer J, Tomasello E, Cebecauer M, Colonna M, Vivier E et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 2005; 106: 1711-1717.
60. Xue W, Zrnder L, Miething C, Dickins RA, Hemando E, Krizhanovsky V et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656-660.
61. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ et al. Induction of tumor cell apoptosis in vivo Increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003; 170: 4905-4913.
62. Rad AN, Pollara G, Sohaib SM, Chiang C, Chain BM, Katz DR. The differential influence of allogeneic tumor cell death via DNA damage on dendritic cell maturation and antigen presentation. Cancer Res 2003; 63: 5143-5150.
63. McBride S, Hoebe K, Georgel P, Janssen E. Cell-associaled double-stranded RNA enhances antitumnor activity through the producUon of type I IFN. J Immunol 2008; 177: 6122-6128.
64. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 2007; 13: 851-856.
65. do Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 2006; 13 118-137.
66. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6: 24-37.
67. Badn W, Hegardt P, Fellert MA, Darabi A, Esbjornsson M, Smith KE et al. Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-gamma-secreting glioma cells. Scand J Immunol 2007; 65: 289-297.
68. Pelaez B, Campillo JA, Lopez-Asenjo JA, Subiza JL. Cyclophosphamide induces the development of early myeloid calls suppressing tumor cell growth by a nitric oxide-dependent mechanism. J Immunol 2001; 166: 6608-6615.
69. DeLong P, Tanaka T, Kruklitis R, Henry AC, Kapoor V, Kaiser LR et al. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res 2003; 63: 7845-7852.
70. Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 2001; 166 6483-6490.
71. Weaver CT, Hatton RD, Mangan PR, Harlington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25: 821-852.
72. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K et al. IL-23 promotes tumour incidence and growth. Nature 2006; 442 461-465.
73. Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J Immunol 2007; 178: 7571-7580.
74. Sporri R, Reis a Sousa C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol 2005; 6: 163-170.